What were Leqvio’s Q3 2026 sales and Novartis’s peak-sales outlook?
In Drugnews’s November 3, 2026 analysis of Novartis’s October 27 results, Leqvio (inclisiran) generated US$506 million in Q3 2026 sales, up 64% from US$308 million a year earlier. The article reports management’s peak-sales outlook at more than US$4 billion. That outlook is a forecast, and ORION-4 cardiovascular outcome results are a separate evidentiary question.
| Measure | Reported result | Basis |
|---|---|---|
| Q3 2026 revenue | US$506 million | Reported sales |
| Year-over-year growth | 64% | As reported in the original analysis |
| Prior-year quarter | US$308 million | Comparable sales period |
| Management peak-sales outlook | More than US$4 billion | Forward-looking; not booked revenue |
The original article’s prediction of ORION-4 success is an editorial forecast. It is not treated here as a completed trial result or a new approved indication.